Contact Alcon India for Trial Locations
Karnataka, 560048, India
NCT Number: NCT02380248
The purpose of this study is to evaluate the efficacy and safety of Systane® Gel Drops in dry eye subjects following 90 days of QID (4 times/day) dosing.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Karnataka, 560048, India
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Systane® Gel Drops
Time frame: Baseline (Day 0), Day 45, Day 90
Corneal staining was assessed by the Investigator through slit-lamp examination and reported on a scale of 0-3, where 0=normal (no staining) and 3=severe (numerous coalescent macropunctate areas and/or patches), for the 5 quadrants of each eye. The scores at each visit were summed by eye for each subject. The overall corneal staining score for the subject at each visit was then computed as the average of the sum from both eyes. Thus, the overall scores ranged between 0-15 with higher scores reflecting more damage to the corneal surface.
Alcon Research
Industry
Clinical Evaluation of Systane® Gel Drops on Corneal Staining in Indian Subjects With Dry Eye
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07089511
Dry Eye, Dry Eye Syndromes
Milan, Italy
View Trial DetailsNCT06346340
Dry Eye, Dry Eye Syndromes
Laguna Hills, California, United States
View Trial DetailsNCT07675460
Acne Cystic, Choroidal Thickness
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT04418999
Allergy, Corneal Diseases
Chicago, Illinois, United States
View Trial Details